Quintiles Transnational Holdings Inc (Q) : 3i Investments Plc reduced its stake in Quintiles Transnational Holdings Inc by 36.24% during the most recent quarter end. The investment management company now holds a total of 3,958,501 shares of Quintiles Transnational Holdings Inc which is valued at $289,841,443 after selling 2,250,000 shares in Quintiles Transnational Holdings Inc , the firm said in a disclosure report filed with the SEC on Jul 19, 2016.Quintiles Transnational Holdings Inc makes up approximately 100.00% of 3i Investments Plc’s portfolio.
Other Hedge Funds, Including , Acadian Asset Management reduced its stake in Q by selling 5,077 shares or 16.44% in the most recent quarter. The Hedge Fund company now holds 25,808 shares of Q which is valued at $1,889,662. Quintiles Transnational Holdings Inc makes up approx 0.01% of Acadian Asset Management’s portfolio.Cutler Group Lp boosted its stake in Q in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 1,500 shares of Quintiles Transnational Holdings Inc which is valued at $106,590. Quintiles Transnational Holdings Inc makes up approx 0.01% of Cutler Group Lp’s portfolio.
Quintiles Transnational Holdings Inc opened for trading at $72.14 and hit $73.32 on the upside on Wednesday, eventually ending the session at $73.22, with a gain of 1.50% or 1.08 points. The heightened volatility saw the trading volume jump to 10,11,051 shares. Company has a market cap of $8,762 M.
On the company’s financial health, Quintiles Transnational Holdings Inc reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.86. The company had revenue of $1108.00 million for the quarter, compared to analysts expectations of $1118.63 million. The company’s revenue was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.72 EPS.
Many Wall Street Analysts have commented on Quintiles Transnational Holdings Inc. Quintiles Transnational Holdings Inc was Upgraded by Avondale to ” Mkt Outperform” on Jul 12, 2016. Quintiles Transnational Holdings Inc was Downgraded by Wells Fargo to ” Market Perform” on May 12, 2016. Shares were Downgraded by Robert W. Baird on May 4, 2016 to ” Neutral” and Lowered the Price Target to $ 74 from a previous price target of $76 .
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services including commercial services such as contract pharmaceutical sales forces and healthcare business services such as phase research market access and consulting and health information analytics and technology consulting.